25 results about "Tropomyosin" patented technology

This disclosure relates to bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and to methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such bivalent compounds.

This invention relates to drug conjugates useful for localized treatment of diseases or disorders of the middle ear and / or inner ear. Methods of treating diseases or disorders of the middle ear and / or inner ear, pharmaceutical compositions comprising the conjugates, and methods of inhibiting a Tropomyosin receptor kinase are also provided.

The invention relates to the technical field of allergen proteins and antigen epitopes, and discloses an Antarctic krill allergen and an identification method and application of the Antarctic krill allergen, the Antarctic krill allergen and the antigen epitopes are used for identifying the Antarctic krill allergen and the antigen epitopes, and the identification method comprises the steps of Antarctic krill crude protein extraction, Antarctic krill allergen screening and identification. Extracting an antarctic krill map and verifying allergens; analyzing the homology of the euphausia superba and analyzing the conformation of tropomyosin of the euphausia superba; carrying out euphausia superba tropomyosin epitope analysis; and allergens and epitopes of the euphausia superba are applied. According to the invention, the antarctic krill allergen is identified as tropomyosin, eight antigen epitopes of the antarctic krill tropomyosin allergen are ascertained, the stability change rule in the hot working process is analyzed by utilizing the identified antarctic krill allergen and antigen epitopes, and the result shows that the stability of the antarctic krill allergen is greatly improved under the processing condition of 140 DEG C or below. And the conformation of the tropomyosin of the euphausia superba and the binding capacity of the tropomyosin with protein immune globulin E or immune globulin G are kept stable.

The present invention provides a kit for detecting antigen myosin 1 IgG antibodies, which is composed of antigen protein Tropomyosin 1 (tropomyosin 1), a solid phase carrier, a standard, a positive quality control product, a negative quality control product, a labeled antibody, a substrate color developing solution, an antibody diluent, an antigen diluent, a sample dilution buffer, a washing solution, a stop solution, etc. The present invention utilizes the target antigen Tropomyosin 1 corresponding to the anti-Tropomyosin 1 IgG antibody, and uses human anti-label peptide IgG as a standard for quantitative detection to perform anti-Tropomyosin 1 IgG antibody detection on the antigen-antibody complex formed in the serum. The kit of the present invention is easy to operate, has very good reagent stability, is easy to store, and fills the gap in identifying biomarkers for patients with immune nephrotic syndrome at home and abroad.

This invention belongs to the field of pharmaceutical synthesis technology, specifically relating to a diarylurea derivative, its preparation method, and its application. The diarylurea derivative of this invention is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which exhibits high inhibitory activity against wild-type (WT), mutant G595R, and G667C tropomyosin receptor kinase (TRK), and can be used to treat NTRK fusion-positive locally advanced or metastatic solid tumors.

The invention belongs to the technical field of genetic engineering, and particularly relates to truncated tropomyosin, a nucleic acid molecule and application of the truncated tropomyosin. The truncated tropomyosin is based on an alpha-helical structure of tropomyosin, and is obtained by taking glutamic acid (E26) at the 26th site, glutamine (Q51) at the 51st site or glutamic acid (E73) at the 73rd site as a truncation site. By reasonably designing a truncation site and further replacing the secretion signal peptide, the expression quantity of the protein in a recombinant expression system is remarkably improved, the immunogenicity of the protein is effectively reserved, and the protein can be used for precise diagnosis of allergy and development of anti-allergic vaccines.

The invention relates to the technical field of biology, and particularly discloses marine bacterial protease as well as a coding gene, a preparation method and application thereof. The invention provides protease 4SP5-519 capable of specifically degrading allergenic tropomyosin in aquatic products and reducing the sensitization of the allergenic tropomyosin, and the protease 4SP5-519 is applied to improving the food safety of the aquatic products.

Disclosed herein are compounds and pharmaceutical compositions useful for treating, preventing, reducing, or ameliorating diseases or conditions associated with neurodegenerative disorders. Without being bound by theory, the disclosed compounds and compositions are believed to selectively target tropomyosin receptor kinase A (TrkA) receptor-mediated pro-survival signaling pathways or the nerve growth factor (NGF) or the neurosteroid dehydroepiandrosterone (DHEA) and may prevent, treat, reduce, or ameliorate neurodegeneration.

Provided herein are mannose receptor ligand-containing compounds, methods of delivering said compounds to subjects, and methods of treating diseases (e.g., central nervous system diseases) and symptoms thereof in a subject using said compounds.

The invention relates to the technical field of food analysis, and provides a method for analyzing the sensitization effect of natural carbohydrate chains on food allergens, which comprises the following steps: extracting and purifying tropomyosin freeze-dried powder in food muscle tissues, identifying the types of carbohydrate chains in the tropomyosin freeze-dried powder, and analyzing the types of glucosidic bonds; removing an N-carbohydrate chain and an O-carbohydrate chain in the tropomyosin freeze-dried powder by using one or more of a PNGase F enzyme removal method, a beta-elimination method and a trifluoromethanesulfonic acid method, so as to obtain a deglycoprotein; a phenol-sulfuric acid method, SDS-PAGE (Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis) and PAS (Polyacrylamide Sulfate) dyeing are used for evaluating the anti An in vitro test and an in vivo test are used to evaluate the effect of the desugaring treatment on the allergenicity of tropomyosin. By analyzing the regulation influence of the natural carbohydrate chain on the allergenicity of the penaeus chinensis tropomyosin, a foundation is laid for deep research on the allergenicity of the penaeus chinensis tropomyosin, and an innovative perspective of analyzing the allergenicity characteristics of the penaeus chinensis tropomyosin is provided.

The present invention discloses compositions, such as pharmaceutical compositions, as well as methods for use in the treatment and / or prevention of cancer, preferably of an ILC2 rich cancer. The pharmaceutical composition of the invention comprises a Tropomyosin receptor kinase A inhibitor and is administered concomitantly, separately or staggered in time with an immune therapy.

The invention provides a crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, methods of inhibiting tropomyosin-related kinase and / or c-FMS, and methods of treating medical diseases and conditions, such as pain.

The present invention is in the field of medicinal chemistry and relates to a novel pyrazolopyridine derivative and its preparation and use as therapeutic agents, in particular as TRK inhibitors. Compounds of general formula (I) and their geometric isomers or pharmaceutically acceptable salts thereof and their preparation. Preferred compounds have activity as protein kinase inhibitors, in particular tropomyosin receptor kinase (TRK) inhibitors.

In some aspects, the disclosure provides antibody-based reagents that specifically bind a tropomyosin receptor kinase B (TrkB) isoform that is associated with cancers. In some embodiments, the isoform is TrkB.T1. In some embodiments, the antibody or antibody derivative specifically binds a polypeptide comprising, consisting essentially of, or consisting of the sequence FVLFHKIPLDG (SEQ ID NO:1), or a sequence with at least 80% sequence identity thereto. In other aspects, the disclosure provides methods of producing the antibody or antibody derivative, related hybridomas, and methods of detecting and treating cancers incorporating use of the disclosed antibody reagents.

This disclosure relates to bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and to methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such bivalent compounds.

Provided herein are proteins that include a Vascular Endothelial Growth Factor A (VEGF-A) protein binding domain; proteins that include an Epstein-Barr Virus BCL-2 homolog (BHRF1) protein binding domain; proteins that include a Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) RBD protein binding domain; proteins that include an Interleukin-7 receptor subunit alpha (IL7R-α) protein binding domain; proteins that include a Programmed death-ligand 1 (PD-L1) protein binding domain; proteins that include a Tropomyosin-receptor kinase A (Trk-A) protein binding domain; and proteins that include an Interleukin-17 (IL-17A) protein binding domain.

The present invention belongs to the field of medicinal chemistry, and particularly relates to an N-(3-fluorobenzyl)-1H-indazole-5-amine derivative having a structure as shown in general formula (I), and the preparation and the use thereof. The N-(3-fluorobenzyl)-1H-indazole-5-amine derivative having a structure as shown in general formula (I), and a stereoisomer, pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof provided in the present invention have an activity as a protein kinase inhibitor, particularly an inhibitory activity against tropomyosin receptor kinase (TRK).

The invention provides a shrimp tropomyosin specific nano-antibody and application thereof. The specific nano-antibody is at least one of a nano-antibody Nb48, a nano-antibody Nb55, a nano-antibody Nb78, a nano-antibody Nb84, a nano-antibody Nb88, a nano-antibody Nb110, a nano-antibody Nb115 or a nano-antibody Nb141; the specific nano antibody comprises three complementary determining regions, namely a CDR1 (complementary determining region), a CDR2 (complementary determining region) and a CDR3 (complementary determining region); and for the nano antibody Nb48, the amino acid sequence of the CDR1 is as shown in SEQ ID NO.1, the amino acid sequence of the CDR2 is as shown in SEQ ID NO.2, and the amino acid sequence of the CDR3 is as shown in SEQ ID NO.3. The shrimp tropomyosin specific nano antibody disclosed by the invention is short in preparation period, low in cost and high in stability, and can realize economical, efficient, high-sensitivity and rapid detection of allergen shrimp tropomyosin in food.

The application belongs to the field of pharmaceutical chemistry, and particularly relates to a Tropomyosin Receptor Kinase A (TrkA) inhibitor and a preparation method and application thereof, a structural formula of which is shown as formula (I); the compound provided by the application has high inhibitory activity on TrkA and good subtype selectivity. The compound has potential application in analgesic treatment, including but not limited to chronic pain caused by osteoarthritis, cancer pain, back pain and the like; the compound also has potential anticancer activity.

Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5b-]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.

Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and / or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and / or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

The invention relates to the technical field of biology. The invention provides a method for reducing allergenicity based on an alpha-dicarbonyl compound modified tropomyosin allergen epitope, which comprises the following steps: analyzing the epitope in tropomyosin, ascertaining a glycosylation modification site in the epitope, and directionally modifying the epitope by adopting the alpha-dicarbonyl compound, so as to reduce the allergenicity of the tropomyosin allergen epitope. Directional resistance and control of allergenicity of tropomyosin are realized, technical support is provided for guaranteeing body health and life quality of aquatic food allergy patients in China, and research and development of low-allergy or non-allergy aquatic food are further promoted.

The invention provides a T cell epitope fusion protein aiming at main allergens of Fujian oysters and application of the T cell epitope fusion protein. The T cell epitope fusion protein comprises four T cell epitopes of allergen tropomyosin (Craa a 1) and two T cell epitopes of allergen arginine kinase (Craa a 2); a KK connexon is used between the epitopes of the same allergen, and the epitopes of different allergens are connected in series by using an EAAAK connexon; the amino acid sequences of the four T cell epitopes of the Cra a 1 are as shown in SEQ ID NO: 1-4, and the amino acid sequences of the two T cell epitopes of the Cra a 2 are as shown in SEQ ID NO: 5-6. The T cell epitope fusion protein solves the problems of high cost of hybrid peptides and limitation of monoallergens in oyster allergy treatment, can be applied to preparation of desensitization preparations, prevention of oyster allergic diseases and reduction of side effects in immunotherapy, and provides a new strategy for development of efficient broad-spectrum oyster allergy oral immunotherapy preparations.